ESC Meeting to Present Key Statin Trial and Heart Attack Care Studies
The European Society of Cardiology meeting will unveil results from the STAREE trial, which examined statin use for primary prevention in adults aged 70 and older. Other studies will address heart attack triage and new anticoagulant therapies, including the failed milvexian trial. The findings are expected to inform clinical decisions for millions of older adults.
The STAREE trial's roughly 10,000 participants represent the first major randomized evidence on whether statins benefit relatively healthy adults aged 70 and older without prior atherosclerotic disease. Its results could settle a long-running debate about routine statin use in this population, given concerns about muscle pain and fatigue side effects.
The conference also features the LIBREXIA ACS trial, halted early after milvexian failed to reduce major adverse cardiovascular events in recent heart attack survivors. Additional presentations include AMUNDSEN testing evolocumab before percutaneous coronary intervention, the PRESC1SE-MI trial validating the rapid 0/1-hour troponin algorithm, and ACACIA-HCM showing aficamten met primary endpoints for symptomatic nonobstructive hypertrophic cardiomyopathy.
The STAREE findings could directly influence prescribing decisions for millions of older adults worldwide, potentially reshaping preventive cardiology guidelines for the elderly. If statins prove beneficial in this demographic, more seniors may receive treatment; if not, clinicians might adopt more conservative approaches. The milvexian failure may also temper expectations for factor XIa inhibitors, while positive results for aficamten could offer new hope for hypertrophic cardiomyopathy patients who currently lack effective options.